Recombinant Mouse IGSF2/CD101 Fc Chimera Protein, CF

Recombinant Mouse IGSF2/CD101 Fc Chimera (Catalog # 3368-CD) inhibitsanti-CD3 antibody induced human T cell proliferation. The ED50 for this effectis 1.4‑8.4 μg/mL.

2 μg/lane of Recombinant Mouse IGSF2/CD101 was resolved with SDS-PAGE underreducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Bluestaining, showing bands at 121-150 kDa and 240-280 kDa, respectively.

• Reactivity: Mu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Mouse IGSF2/CD101 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit anti-CD3-induced proliferation of stimulated human T cells. The ED₅₀ for this effect is 1.4-8.4 μg/mL.
• Source: Mouse myeloma cell line, NS0-derived mouse IGSF2/CD101 protein
  

  Mouse CD101 (Gln21-Phe974) Accession # A8E0Y8	IEGRMDP	Mouse IgG2a (Glu98-Lys330)
  N-terminus		C-terminus

• Accession #: A8E0Y8
• N-terminal Sequence: No results obtained. Gln21 inferred from enzymatic pyroglutamate treatment revealing Arg22.
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Purity Statement: Antigen Affinity-purified
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 133 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 121-150 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 400 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Mouse IGSF2/CD101 Fc Chimera Protein, CF

• CD101 antigen
• CD101 molecule
• CD101
• Cell surface glycoprotein V7
• EWI101
• EWI-101
• Glu-Trp-Ile EWI motif-containing protein 101
• IGSF2
• Leukocyte Surface Protein
• member 2
• V7

Background

CD101, also known as Immunoglobulin Superfamily member 2 (IGSF2) or cell surface glycoprotein V7 (V7), is a 130-145 kDa type 1 transmembrane glycoprotein within the very large Ig superfamily (1). Ig superfamily members participate in diverse functions including cell-cell recognition and adhesion, soluble molecules and specific antigen recognition, and are grouped based on the presence of a characteristic Ig domain fold. Mature mouse CD101 consists of a large extracellular domain (ECD) containing a Glu-Trp-Ile (EWI) motif and 7 Ig-like V-type domains, a single transmembrane domain, and a short cytoplasmic domain (1, 2). The mouse CD101 ECD shares 71% and 87% amino acid sequence identity with human and rat CD101 ECD, respectively. The exact biological functions, interacting ligands and mode of signal transduction for CD101 currently remain unclear. CD101 expression has been found on dermal dendritic cells (DCs), granulocytes, monocytes, activated T cells, and CD4⁺ CD25⁺ FoxP3⁺ T regulatory cells (Tregs) (2-5). CD101 expression has been linked to immune suppression by Tregs in humans (6), with ligation of CD101 on DCs inducing IL-10 expression (2) and ligation on activated T cells blocking IL-2 expression (7). Both of these effects down-regulate T cell activity. Notably, in mice, CD101 expression on CD62L⁺⁺ Tregs identifies a population of cells that have potent suppressor activity (5). In humans, reduced CD101 expression on mucosal CD8⁺ T cells has been linked to increased tissue inflammation in both intestinal (8) and pulmonary mucosa (9). In both mouse and human, mutations in CD101 have been associated with increased susceptibility for diabetes (10, 11). CD101 expression may act as a potential biomarker for CD4⁺ CD56⁺ blastic tumors (12) and inflammatory bowel disease activity (13), and missense variants of its gene have been associated with increased risk of HIV-1 acquisition (14).

1. Stipp, C. et al. (2001) J. Biol. Chem. 276:40545.
2. Bouloc, A. et al. (2000) Eur. J. Immunol. 30:3132.
3. Rivas, A. et al. (1995) J. Immunol. 154:4423.
4. Ruegg, C. et al. (1995) J. Immunol. 154:4434-CD.
5. Fernandez, I. et al. (2007) J. Immunol. 179:2808.
6. Hua, J. et al. (2015) J. Immunol. 195:3642.
7. Soares, L. et al. (1998) J. Immunol. 161:209.
8. Brimnes, J. et al. (2005) J. Immunol. 174:5814.
9. Kumar, B. et al. (2017) Cell Rep. 20:2921.
10. Rainbow, D. et al. (2011) J Immunol. 187:325.
11. Okuno, M. et al. (2017) J Diabetes Investig. 8:286.
12. Meyer, N. et al. (2005) J. Invest. Dermatol. 124:668.
13. Schey, R. et al. (2016) Mucosal Immunol. 9:1205.
14. Mackelprang, R. et al. (2017) PLoS Pathog. 13:e1006703.

Bioinformatics

• Uniprot:
  • A8E0Y8()